Carlsmed, a company pioneering artificial intelligence (AI)-enabled personalized spine surgery, reported successful completion of the first aprevo cervical procedure on July 14. The procedure was performed by Joseph Osorio, MD, Ph.D., Chief of Spine Surgery in the Department of Neurological Surgery at UC San Diego (UCSD) Health in San Diego, Calif.

aprevo devices are engineered to match each patient’s unique anatomical and alignment needs through the company’s proprietary AI-powered surgical planning platform and digital production system. Dr. Osorio has extensive experience using the aprevo platform for lumbar spine fusion procedures.

“Leveraging the aprevo system for cervical fusion surgery allows a level of alignment which I believe is not achievable with traditional implants,” Dr. Osorio told the press. “The ability to customize each device to the patient’s unique pathology and anatomy represents a meaningful advancement for my practice.”

aprevo cervical was granted breakthrough status from the U.S. Food and Drug Administration (FDA) in 2023, received FDA clearance last year, and the company expects U.S. commercial launch in 2026.

“On the heels of our IPO, this first cervical procedure represents an exciting milestone as we expand our personalized surgical solutions to the cervical spine,” said Mike Cordonnier, chairman and CEO of Carlsmed. “We are proud to partner with Dr. Osorio and UCSD Health to bring this breakthrough technology to patients. Our goal is to reduce the need for revision surgeries, improve outcomes, and enhance value across the healthcare system as we work toward establishing a new standard of care.”

Earlier this year, the company launched a state-of-the-art digital production line that will enable the firm to deliver its aprevo personalized spinal fusion implants to hospitals in less than 10 days.